This project may have a substantial social and economic impact on health. Immunotherapy treatments with CAR T cells cost hundreds of thousands of euros per patient. Radiopharmaceutical drug doses cost tens of thousands of euros per patient, with several doses being required per patient, although responses in patients often last only a few months. There is a clear need for finding the optimal use of those drugs, alone or in combination with other treatments, to optimize health system costs while, at the same time, improving response and survival times.

Mathematics can even help in trying to cure late-stage cancers using combination approaches based on these treatments. The same can be said about fibrous dysplasia, a non-lethal disease but still difficult to manage. Improving the outcome of current clinical trials with denosumab and/or finding the best combination schemes with other treatments such as bisphosphonates may have a direct impact on the health of the patients with this pathology.